Page 60 - Read Online

Page 150 Bibi et al. J Transl Genet Genom 2024;8:119-161 https://dx.doi.org/10.20517/jtgg.2023.50

CONCLUSION
Despite strides in immunotherapy and gene therapy, overcoming the immunosuppressive traits of tumors
and ensuring consistent treatment responses remains challenging. The necessity for tailored and integrated
approaches is underscored, offering hope for future strategies aimed at improving therapeutic outcomes for
prostate cancer patients. Comprehending the array of overexpressed and predominantly expressed proteins
in prostate cancer provides potential avenues for immunotherapeutic interventions. Each protein presents
distinct challenges and prospects, underscoring the imperative for ongoing research to refine treatment
modalities and enhance patient outcomes. The integration of precise gene editing techniques with efficient
gene delivery methods holds great promise for advancing prostate cancer treatment. Targeted strategies and
continuous research are essential to tackle challenges and optimize outcomes in the evolving landscape of
prostate cancer gene therapy. Examining combination therapy strategies, particularly the integration of
immunotherapy with chemotherapy, radiation, or hormone therapy, holds potential for identifying
synergistic effects. Such investigations may open new avenues to enhance treatment efficacy in prostate
cancer. The exploration of potential new targets, creative delivery approaches, and innovative therapy
combinations is paramount. By highlighting these future prospects, it will guide research efforts and spark
fresh ideas in the field.

DECLARATIONS
Authors’ contributions
Conceived and designed the study; performed data collection and analysis; drafted the manuscript; revised
the manuscript critically for important intellectual content; approved the final version to be published:
Bibi R
Contributed to the conceptualization of the study; contributed to data collection and analysis; Reviewed and
provided feedback on the manuscript; approved the final version to be published: Sarkar K
Both authors contributed to writing and critically revising the manuscript.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024

REFERENCES
1. Rehman LU, Nisar MH, Fatima W, et al. Immunotherapy for prostate cancer: a current systematic review and patient centric
perspectives. J Clin Med 2023;12:1446. DOI PubMed PMC
2. Tewari AK, Stockert JA, Yadav SS, Yadav KK, Khan I. Inflammation and prostate cancer. Adv Exp Med Biol 2018;1095:41-65. DOI
PubMed